Form 4: Baker Bros. Advisors Boosts Entrada Therapeutics Stake

Baker Bros. Advisors and its principals acquired additional common stock in Entrada Therapeutics, increasing their indirect beneficial ownership.

Summary

• Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Felix Baker, and Julian Baker reported the acquisition of common stock in Entrada Therapeutics, Inc. [TRDA].
• The transactions occurred on November 20, 2025, and were made pursuant to a Rule 10b5-1 plan.
• A total of 28,867 shares of common stock were acquired across four transactions.
• The shares were purchased at weighted average prices of $9.0688 and $9.0728.
• The price ranges for these transactions were $8.82 to $9.25 and $8.85 to $9.20, respectively.
• Following these transactions, the reporting persons indirectly beneficially own a total of 5,072,730 shares of Entrada Therapeutics common stock.
• The indirect ownership is held through 667, L.P. (381,338 shares) and Baker Brothers Life Sciences, L.P. (4,691,392 shares).
• The reporting persons are identified as 10% owners and directors of Entrada Therapeutics.

Sentiment

Score: 8

Explanation: The acquisition of additional common stock by Baker Bros. Advisors and its principals, who are also 10% owners and directors, demonstrates strong conviction in Entrada Therapeutics' value and future prospects.

Positives

• Significant insider buying by Baker Bros. Advisors and its principals, who are also 10% owners and directors, indicates strong confidence in Entrada Therapeutics' future prospects.
• The acquisition of 28,867 shares at prices around $9.07 suggests that key institutional investors and management see value at current levels.
• Increased indirect beneficial ownership by these key stakeholders now totals 5,072,730 shares, reinforcing their long-term commitment to the company.

Future Outlook

The filing does not contain forward-looking statements or guidance from the company, as it is a report of past insider transactions.

Industry Context

This Form 4 indicates continued investment by a prominent biotech-focused investment firm (Baker Bros. Advisors) in Entrada Therapeutics, a company likely operating in the biotechnology or pharmaceutical sector. Such investments can signal confidence in the company's drug pipeline or strategic direction within the competitive biotech landscape.

Related Party Transactions

• The reported transactions are related party transactions, as they involve significant shareholders and directors (Baker Bros. Advisors and its principals) acquiring shares of the issuer.

Stakeholder Impact

• Shareholders: Existing shareholders may view this insider buying as a positive signal, potentially increasing confidence in the stock and its future performance.
• Employees: No direct impact mentioned, but a strong investor base can contribute to company stability.

Key Dates

Recommendation

The significant insider buying by Baker Bros. Advisors, a highly respected biotech investor, and its principals (who are also directors and 10% owners), signals strong confidence in Entrada Therapeutics' valuation and future potential. Such a move by informed insiders often precedes positive developments or indicates a belief that the stock is undervalued, making it a compelling 'buy' signal for other investors.

Keywords

Entrada Therapeutics, TRDA, Baker Bros. Advisors, insider buying, beneficial ownership, common stock acquisition, institutional investment, biotech, pharmaceutical